In yet another pharmaceutical deal, Endo International plc (Nasdaq: ENDP) is buying Dava Pharmaceuticals for $575 million in cash.

Dava, headquartered in Fort Lee, New Jersey, specializes in marketed, pre-launch and generic pharmaceuticals, including Amoxicillin capsules and Penicillin.

Dublin-based Endo is a specialty health care company that develops, manufactures, markets and distributes branded and generic pharmaceutical products through its operating companies. The deal enhances Endo's commercialization and development possibilities. The group has a U.S. headquarters in Malvern, Pennsylvania.

The transaction includes another potential $25 million based on certain sales milestones.

Oppenheimer & Co. is acting as Dava's lead financial adviser, while Jefferies LLC also provides financial advice. Dechert LLP is provided legal counsel to Dava. Skadden Arps Slate Meagher & Flom LLP is Endo's legal adviser. 

Recent pharmaceutical deals include H. Lundbeck A/S' deal for Chelsea Therapeutics International Ltd., and Merck's agreement to buy Idenix Pharmaceuticals Inc. 


Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.